Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 31, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 31, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 599 Common Stock at $507.84 ($304,198) on August 31, 2026; holds 333,344 after (Indirect).
  • Open-market sale: disposed of 794 Common Stock at $508.92 ($404,082) on August 31, 2026; holds 332,550 after (Indirect).
  • Open-market sale: disposed of 810 Common Stock at $509.84 ($412,967) on August 31, 2026; holds 331,740 after (Indirect).
  • Open-market sale: disposed of 4,217 Common Stock at $510.93 ($2,154,598) on August 31, 2026; holds 327,523 after (Indirect).
  • Open-market sale: disposed of 1,600 Common Stock at $511.75 ($818,801) on August 31, 2026; holds 325,923 after (Indirect).
  • Open-market sale: disposed of 678 Common Stock at $513.50 ($348,154) on August 31, 2026; holds 325,245 after (Indirect).
  • Open-market sale: disposed of 762 Common Stock at $514.32 ($391,913) on August 31, 2026; holds 324,483 after (Indirect).
  • Open-market sale: disposed of 40 Common Stock at $514.96 ($20,598) on August 31, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on August 31, 2026; holds 27,910 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,855,312 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-31Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-08-31Open-market saleCommon Stock599$508$304.2K333,344
2026-08-31Open-market saleCommon Stock794$509$404.1K332,550
2026-08-31Open-market saleCommon Stock810$510$413.0K331,740
2026-08-31Open-market saleCommon Stock4,217$511$2.2M327,523
2026-08-31Open-market saleCommon Stock1,600$512$818.8K325,923
2026-08-31Open-market saleCommon Stock678$514$348.2K325,245
2026-08-31Open-market saleCommon Stock762$514$391.9K324,483
2026-08-31Open-market saleCommon Stock40$515$20.6K324,443
2026-08-31Option exercise/conversionStock Option9,500——27,910

Key Dates

DateDescription
2026-08-31Option exercise/conversion (9,500 shares)
2026-08-31Open-market sale (599 shares)
2026-08-31Open-market sale (794 shares)
2026-08-31Open-market sale (810 shares)
2026-08-31Open-market sale (4,217 shares)
2026-08-31Open-market sale (1,600 shares)
2026-08-31Open-market sale (678 shares)
2026-08-31Open-market sale (762 shares)
2026-08-31Open-market sale (40 shares)
2026-08-31Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.